Gilead Sciences Inc.’s (GILD) Genvoya has received FDA approval for the treatment of HIV-1 infection. Genvoya is a single tablet regimen, which is a combination of elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF.